- About |
- Contact Us |
- Site Map |
- Privacy Policy |
- Terms Of Use |
- Feedback
55. Drug Resistance
CUSTOM BOOKS
Select, organize, download, and save your choice of chapters into a single PDF file for printing and distribution. This is a free service.
My DCPP
Log in to view your saved custom books
CHAPTER INFO
Editors/Authors: Ramanan Laxminarayan, Zulfiqar A. Bhutta, Adriano Duse, Philip Jenkins, Thomas O'Brien, Iruka N. Okeke, Ariel Pablo–Mendez, and Keith P. Klugman
Pages: 22
Region
East Asia and Pacific
Europe and Central Asia
High Income OECD
South Asia
Sub-Saharan Africa
Disease / Condition
Diarrheal Disease
Helminth Infections
HIV/AIDS
Infectious Diseases
Malaria
Maternal Conditions
Respiratory Diseases
Respiratory Infections
Sexually Transmitted Infections
Tuberculosis
Abstract
The control of infectious diseases is seriously threatened by the steady increase in the number of microorganisms that are resistant to antimicrobial agents. Once resistance has emerged in a population, it can spread both geographically and between age groups. The problem is particularly severe in developing countries, where patients have less access to or are unable to afford second–line treatments. Because these are typically more expensive, the economic impact of drug resistance in developing countries may be substantial. Factors that contribute to disease, such as poor hygiene and unreliable water supplies, exacerbate the problem.
Interventions to address the problem of drug resistance are often the same as those that reduce the burden of disease. Reducing disease diminishes the need for drug treatment, which lowers the likelihood that resistant strains will emerge. In addition, the appropriate choice of drug treatment is an important step in delaying the evolution of drug resistance. Education, professional accountability, and improved communication between patients and providers are necessary.
Antimicrobial resistance is a global challenge. It is important for governments to ensure that the effectiveness of our current arsenal of anti–infectives is not depleted too rapidly. Sustaining gains in life expectancy by means of the introduction of effective drugs to treat infectious diseases requires a willingness to invest in interventions both to extend the therapeutic life of existing drugs and to discover and develop new ones.
Sections
Click on the links below to read the full text.
